Advice
in the absence of a submission from the holder of the marketing authorisation
cobicistat (Tybost®) is not recommended for use within NHS Scotland.
Indication under review: Pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice77KB (PDF)
Medicine details
- Medicine name:
- cobicistat (Tybost)
- SMC ID:
- 933/13
- Indication:
- Pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 May 2014